Arformoterol
Arformoterol.svg
Arformoterol ball-and-stick model.png
Clinical data
Trade namesBrovana
Other namesArformoterol tartrate (USAN US)
AHFS/Drugs.comMonograph
MedlinePlusa602023
License data
Routes of
administration
Inhalation
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
Protein binding52–65%
Elimination half-life26 hours
Identifiers
  • N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl) propan-2-yl]amino]ethyl] phenyl]formamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H24N2O4
Molar mass344.411 g·mol−1
  • InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1 checkY
  • Key:BPZSYCZIITTYBL-YJYMSZOUSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Arformoterol, sold under the brand name Brovana among others, is a medication used for the treatment of chronic obstructive pulmonary disease (COPD).[1][2]

It is a long-acting β2 adrenoreceptor agonist (LABA) and it is the active (R,R)-(−)-enantiomer of formoterol.[1] It was approved for medical use in the United States in October 2006.[1] It is available as a generic medicine.[3]

Medical uses

Arformoterol is indicated for the maintenance treatment of bronchoconstriction in people with chronic obstructive pulmonary disease (COPD).[1]

References

  1. ^ a b c d e "Brovana- arformoterol tartrate solution". DailyMed. 13 May 2021. Retrieved 4 March 2022.
  2. ^ Loh CH, Donohue JF, Ohar JA (March 2015). "Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease". Expert Opinion on Drug Safety. 14 (3): 463–72. doi:10.1517/14740338.2015.998196. PMID 25563342. S2CID 7767810.
  3. ^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration. Retrieved 17 May 2022.